Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Zidovudine

Known as: 3'-Azido-2',3'-Dideoxythymidine, Azidothymidine, Antiviral AZT 
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the… Expand
National Institutes of Health

Related topics

Related topics

37 relations

Narrower (18)

3'-azido-3'-deoxyarabinothymidine3'-azido-3'-deoxythymidine monophosphate diglyceride4'-azidothymidine4'-azidothymidine 5'-triphosphate
Expand
Acquired Immunodeficiency SyndromeHIVHIV InfectionsIn Blood
Expand

Broader (2)

Anti-HIV AgentsThymidine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Innovation and trends in the development and approval of antiviral medicines: 1987–2017 and beyond
ABSTRACT 2017 marked the 30th anniversary of the approval of zidovudine (AZT) as the first HIV/AIDS therapy. Since then, more… Expand
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
Review
2018
Review
2018
The ProTide Prodrug Technology: From the Concept to the Clinic
The ProTide technology is a prodrug approach developed for the efficient intracellular delivery of nucleoside analogue… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Review
2018
Review
2018
Structural and Functional Basis of the Fidelity of Nucleotide Selection by Flavivirus RNA-Dependent RNA Polymerases
Viral RNA-dependent RNA polymerases (RdRps) play a central role not only in viral replication, but also in the genetic evolution… Expand
  • figure 3
  • figure 4
  • figure 5
  • table 1
  • table 1
Highly Cited
2010
Highly Cited
2010
Porous metal-organic-framework nanoscale carriers as a potential platform for drug delivery and imaging.
In the domain of health, one important challenge is the efficient delivery of drugs in the body using non-toxic nanocarriers… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2000
Highly Cited
2000
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.
Standard methods for survival analysis, such as the time-dependent Cox model, may produce biased effect estimates when there… Expand
Highly Cited
1999
Highly Cited
1999
Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial
BACKGROUND Many developing countries have not implemented the AIDS Clinical Trials Group 076 zidovudine regimen for prevention of… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Highly Cited
1997
Highly Cited
1997
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
BACKGROUND The new protease inhibitors are potent inhibitors of the human immunodeficiency virus (HIV), and in combination with… Expand
Highly Cited
1994
Highly Cited
1994
Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.
BACKGROUND AND METHODS Maternal-infant transmission is the primary means by which young children become infected with human… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
1989
Highly Cited
1989
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency… Expand
Highly Cited
1987
Highly Cited
1987
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.
We conducted a double-blind, placebo-controlled trial of the efficacy of oral azidothymidine (AZT) in 282 patients with the… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE